HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Tango Therapeutics (NASDAQ:TNGX) but lowered the price target from $16 to $13.
May 28, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Tango Therapeutics but lowered the price target from $16 to $13.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook on its short-term performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100